|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
1998-11-19
|
|
pubmed:abstractText |
Fludarabine, a nucleoside analog that targets both resting and proliferating lymphocytes, is a promising drug for the treatment of autoimmune diseases. We conducted a 2 dose, open label clinical trial to evaluate the toxicity/safety of the fludarabine treatment and its clinical and immunological effects.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0315-162X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
25
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1694-704
|
|
pubmed:dateRevised |
2004-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:9733448-Antigens, CD,
pubmed-meshheading:9733448-Arthritis, Rheumatoid,
pubmed-meshheading:9733448-Dose-Response Relationship, Drug,
pubmed-meshheading:9733448-Female,
pubmed-meshheading:9733448-Humans,
pubmed-meshheading:9733448-Immunosuppressive Agents,
pubmed-meshheading:9733448-Leukocytes, Mononuclear,
pubmed-meshheading:9733448-Lymphocyte Count,
pubmed-meshheading:9733448-Male,
pubmed-meshheading:9733448-Middle Aged,
pubmed-meshheading:9733448-Phenotype,
pubmed-meshheading:9733448-Platelet Count,
pubmed-meshheading:9733448-Time Factors,
pubmed-meshheading:9733448-Treatment Outcome,
pubmed-meshheading:9733448-Vidarabine
|
|
pubmed:year |
1998
|
|
pubmed:articleTitle |
High dose versus low dose fludarabine in the treatment of patients with severe refractory rheumatoid arthritis.
|
|
pubmed:affiliation |
Clinical Investigation Section, Arthritis and Rheumatism Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Controlled Clinical Trial,
Clinical Trial, Phase II,
Clinical Trial, Phase I
|
